Posted: 17 November 2023 Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing process for Arovella’s ALA-101 product candidate to treat cancer patients in upcoming clinical trials. The ALA-101 product incorporates Arovella’s…
Posted: 17 November 2023 Research that could lead to the first early detection blood test for pancreatic cancer has received critical funding from PanKind, The Australian Pancreatic Cancer Foundation. Pancreatic cancer is one of Australia’s biggest killers, with poor…
Posted: 17 November 2023 The Monash Institute of Pharmaceutical Sciences (MIPS) has unveiled a brand new instrument – the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) – which will play a key role in enabling the team to efficiently identify…
Posted: 17 November 2023 Monash University has officially joined the Uniseed investment fund in a collaboration designed to enhance innovation opportunities by amplifying the growth of current and future startup and spinout companies. As a result of Monash…
Posted: 17 November 2023 Burnet Institute has entered into a research licence and option agreement for Burnet Institute’s Stellabody® technology with argenx. The Stellabody® platform Stellabody® is a unique on-target hexamerisation technology that exploits a natural property of…
Posted: 17 November 2023 The Victorian Medtech Skills and Devices Hub (VMH) has released a White Paper identifying the education and training needed to accelerate the growth of Victoria’s vibrant medtech industry. An initiative of the Victorian Government’s Australian Medtech…
Posted: 17 November 2023 Monash University Electrical and Computer Systems Engineering and Bionics Institute research teams have used cutting edge light technology invisible to the human eye to non-invasively image brains to help diagnose hearing impairments in infants and prescribe…
Posted: 14 November 2023 Telix today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan).…
Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that all study visits are complete in its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome (PMS). Top-line results from the trial are expected to be available…
Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) has been presented with the 2023 Australian Growth Company of the Year Award for Health and Life Sciences. Neuren CEO Jon Pilcher commented: “We were very pleased to be recognized…
Posted: 13 November 2023 Peter Mac scientists have been part of a nationwide push to get an important genetic test for blood cancer funded by Medicare. Approved by the federal government earlier this year and now funded in…
Posted: 13 November 2023 Monash University has been named Australia’s top research institution by The Australian in its annual list of the country’s top researchers and research institutions. Of the 250 fields of academic endeavour identified by The Australian Research Magazine…